Differential regulation of somatostatin receptors 1 and 2 mRNA and protein expression by tamoxifen and estradiol in breast cancer cells by Rivera, Juan A et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
Journal of Carcinogenesis
Open Access Research
Differential regulation of somatostatin receptors 1 and 2 mRNA 
and protein expression by tamoxifen and estradiol in breast cancer 
cells
Juan A Rivera, Haydar Alturaihi and Ujendra Kumar*
Address: Fraser Laboratories For Diabetes Research, Department of Medicine, Royal Victoria Hospital, McGill University Health Centre, Montreal, 
Quebec, H3A 1A1, Canada
Email: Juan A Rivera - juan.rivera@mcgill.ca; Haydar Alturaihi - haydar.alturaihi@elf.mcgill.ca; 
Ujendra Kumar* - ujendra.kumar@muhc.mcgill.ca
* Corresponding author    
breast cancer cellsestradiolcell proliferationsomatostatin receptorstamoxifen
Abstract
Somatostatin (SST) inhibition of hormone hypersecretion from tumors is mediated by somatostatin
receptors (SSTRs). SSTRs also play an important role in controlling tumor growth through specific
antiproliferative actions. These receptors are well expressed in numerous normal and tumor
tissues and are susceptible to regulation by a variety of factors. Estradiol, a potent trophic and
mitogenic hormone in its target tissues, is known to modulate the expression of SST and its
receptors. Accordingly, in the present study, we determined the effects of tamoxifen, a selective
estrogen receptor (ER) modulator (SERM), and estradiol on SSTR1 and SSTR2 expression at the
mRNA and protein levels in ER-positive and -negative breast cancer cells. We found that SSTR1
was upregulated by tamoxifen in a dose-dependent manner but no effect was seen with estradiol.
In contrast, SSTR2 was upregulated by both tamoxifen and estradiol. Combined treatment caused
suppression of SSTR1 below control levels but had no significant effect on SSTR2. Treatment with
SSTR1-specific agonist was significantly more effective in suppressing cell proliferation of cells pre-
treated with tamoxifen. Taking these data into consideration, we suggest that tamoxifen and
estradiol exert variable effects on SSTR1 and SSTR2 mRNA and protein expression and
distributional pattern of the receptors. These changes are cell subtype-specific and affect the ability
of SSTR agonists to inhibit cell proliferation.
Introduction
Somatostatin (SST) is a regulatory neuropeptide produced
and secreted by neuroendocrine and inflammatory cells
[1]. It inhibits secretory and proliferative responses in a
number of target cells. In tumors, SST not only blocks hor-
mone hypersecretion but also causes variable degrees of
tumor shrinkage. This antiproliferative effect involves
cytostatic (growth arrest) and cytotoxic (apoptosis)
actions. The biological effect of SST is mediated directly
through a family of five specific high affinity G protein-
coupled receptors termed SSTR1-5. These receptors are
present in most normal and tumor cells [2]. SST also acts
indirectly by reducing the synthesis and secretion of local
and systemic growth promoting factors. Other actions of
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SST include inhibition of angiogenesis, promotion of
vasoconstriction, and modulation of immune cell func-
tion [1,2].
Most solid tumors, including breast, prostate, colon, pan-
creas, brain and liver cancer, express variable levels of
SSTRs and are, therefore, amenable to therapy with SST
analogues [1-3]. The anti-proliferative effects of SST and
its analogue octreotide (OCT) in breast and other cancers
have been clearly demonstrated [4-8]. In animal models
of breast cancer, OCT enhanced the anti-neoplastic effect
of tamoxifen (Tam) or castration [6]. In addition, SST ana-
logues cause a potent reduction in circulating levels of
growth hormone (GH) and its mediator hormone IGF-1,
a potent mitogen in breast and other cancers [9]. Clinical
studies, however, have failed to demonstrate a clinically
significant benefit of OCT administration in addition to
standard therapy with tamoxifen in patients with
advanced breast cancer [10,11]. Although most tumors in
patients with primary breast cancer express SSTRs [12],
lower expression levels in more aggressive tumors may
account for the failure of OCT with Tam in these settings
[13]. Therefore, upregulation of SSTR expression in
aggressive tumors may be a desirable therapeutic goal.
Some of the factors known to upregulate SSTR expression
are also cell proliferation promoters. This presumably
works as a way of endogenous counter regulation [1]. In
several tissues, the sex hormone estradiol (E2) acts as a
potent proliferative and mitogenic factor and is also
known to increase the expression of SST and its receptors
[14-18]. Previous studies have described the variable
effects of E2 on SSTR-mRNA in a number of cell lines [14-
18]. In breast cancer cells, treatment with E2 caused up-
regulated SSTR2-mRNA expression, while Tam had varia-
ble effects depending on the cell line used [14,15]. Visser-
Wisselaar  et al [16] reported induction of SSTR2 and
SSTR3 expression by estrogen in transplantable rat prolac-
tin-secreting pituitary tumor cells. Similarly, Djordijevic et
al [17] reported positive regulation of SSTR2 and SSTR3
alongside inhibition of SSTR1-mRNA by E2 in primary
cultures of female rat pituitary cells expressing all five
SSTRs. In contrast, Kimura et al [18] showed upregulation
of SSTR1, SSTR2, and SSTR3, and drastic downregulation
of SSTR5 in pituitary cells of ovariectomized rats treated
with E2 for one month. From these studies, it is clear that
the precise regulatory role of estrogens on SSTRs and its
implications in cell growth control need further elucida-
tion. Additionally, the role of Tam has not been investi-
gated in detail.
Tam, an ER modulator, potently inhibits the growth of
ER-positive breast cancer cells [19]. Cancer cells from tis-
sues not classically considered estrogen-dependent (e.g.
thyroid, skin, pancreas, liver, glia and meninges) also
show an inhibitory proliferative response to Tam [20-24].
Some of the growth inhibitory properties of Tam are
related to its ability to modify the expression of cell
growth regulators. One such regulator, transforming
growth factor β 1 (TGF-β 1), an inhibitor of cell prolifera-
tion, is upregulated by Tam in both ER-positive and ER-
negative cells [23,25]. In contrast, Tam reduces circulating
levels of IGF-1 [26] and interferes with the IGF-1 receptor
signalling pathway in breast cancer cells by reducing its
phosphorylation and by inhibiting the induction of its
substrate IRS-1 [27,28].
It has been previously shown that SSTR1 and SSTR2 are
highly expressed in breast cancer cells [29] and exert an
inhibitory role on tumor cell proliferation and migration
[30-35]. Accordingly, in the present study, we compare
the effect of Tam and E2, alone or in combination, on
SSTR1 and 2 expressions in breast cancer cells at the
mRNA and protein levels. We report that Tam and E2
exhibited contrasting effects on SSTR1 in ER-positive cells.
However, their actions on SSTR2 expression in ER-nega-
tive cells were similar. We further discuss our findings in
terms of the potential clinical implications of such
interactions.
Materials and methods
Reagents
All the culture cells were obtained from ATCC. Tamoxifen,
Estradiol and 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphe-
nyltetrazolium bromide (MTT) were purchased from
SIGMA (Sigma-Aldrich Canada Ltd). Anti rabbit fluores-
cein isothiocyanate (FITC)-conjugated secondary anti-
bodies were obtained from Jackson Laboratory. Cell
culture medium was from Invitrogen and FBS was pur-
chased from Wisent, Canada. All other reagents were pur-
chased from various suppliers as indicated.
Cell lines
ZR-75-1 and T47D cells were maintained in RPMI
Medium 1640 (Gibco BRL) at standard conditions
(humidified atmosphere, at 37°C, with 5% CO2). MDA-
MB-231 cells were maintained in Leibovitz's L-15
medium at 37°C. Culture media were supplemented with
10% fetal bovine serum (FBS) and standard antifungal-
antibacterial treatment. Culture media were replaced 24
hours prior to treatment with phenol red-free media sup-
plemented with 10% dextran-coated charcoal-treated FBS.
Experiments were conducted on cells between passages 4
to 8.
Cell Treatment
At ~70% confluency, cells were treated with increasing
concentrations (10-10 M, 10-8 M and 10-6 M) of Tam and β -
estradiol (E2), alone or in combination. Time course
experiments (6, 12, 24, 48, and 96 h) showed thatJournal of Carcinogenesis 2005, 4:10 http://www.carcinogenesis.com/content/4/1/10
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changes in mRNA levels were already maximal at 24 h and
sustained thereafter. Thus a 24–36 h exposure time was
used for these experiments. In order to determine the
expression of SSTR1 and SSTR2 by immunocytochemis-
try, cells were treated with 10-6 M of the corresponding
compound for 30–36 h. For cell proliferation experi-
ments, cells were exposed to Tam, E2, both or none for 30
h. 0.5 µM of the nonpeptide SSTR1-specific agonist L-797,
591 [36] or vehicle was added to the medium, and prolif-
eration rate were assessed after an additional 42 h.
RT-PCR
Total RNA was extracted using TRIzol Reagent (Invitro-
gen) according to the manufacturer's instructions. Poten-
tial contaminating genomic DNA was degraded by
incubation with RQ1 ribonuclease-free deoxyribonucle-
ase (Promega Corp.) for 30 minutes at 37°C in the pres-
ence of RNAse inhibitor (Invitrogen). 10 µg of total RNA
was reverse transcribed (RT) using M-MLV-reverse tran-
scriptase (Life technologies Inc), and then amplified using
specific primers for SSTR1, SSTR2 and β -actin as an inter-
nal control. Primers used were as follows:
SSTR1-forward 5' TATCTGCCTGTGCTACGTGC 3' (nt
714–733)
SSTR1-reverse 5' GATGACCGACAGCTGACTCA 3' (nt
911–930)
SSTR2-forward 5' ATCTGGGGCTTGGTACACAG 3' (nt
600–619)
SSTR2-reverse 5' CTTCTTCCTCTTAGAGGAGC 3' (nt
728–747)
β -actin-forward 5' ATCATGAA GTGTGACGTGGAC 3' (nt
885–905)
β -actin-reverse 5' AACCGACTGCTGTCA CCTTCA 3' (nt
1325–1345)
For PCR amplification 4 µl of RT products (cDNA) were
mixed in 100 µl total volume of PCR-buffer (Invitrogen)
containing 2% DMSO, 2.25 mM MgCl2, 50 µM of each
dNTP, 15 pmol of SSTR-primers, and 3 pmol of β -actin
primers.
After initial denaturation at 94°C for 10 min, Taq DNA
polymerase (Invitrogen) (2.5 U/reaction) was added and
samples were subjected to 38 cycles of denaturation at
94°C for 1 min, annealing at 58°C for 45 sec, and exten-
sion at 72°C for 45 sec, followed by a 10 min final exten-
sion at 72°C. 20 µl of the PCR products were fractioned
by electrophoresis in 1.5% agarose gels containing ethid-
ium bromide and visualized under UV light. The specifi-
city of the amplified SSTR products and the corresponding
observed bands were confirmed by Southern blot hybrid-
ization using specific 32P-dCTP-random primer-labelled
SSTR cDNAs. AlphaEaseFC (Alpha Innotech Corporation,
San Leandro, CA) was used for optical density (OD) meas-
urements of the product. OD of target band was corrected
for the corresponding β -actin-band (OD ratio) and then
normalized against the OD ratio of non-treated cells (OD
index).
Immunocytochemistry
Expression of SSTRs in ZR-75-1, T47D and MDA-MB-231
were determined by immunocytochemistry using rabbit
polyclonal antibodies for hSSTR1 and hSSTR2, diluted as
previously described [37,38]. Briefly, cells were grown in
24-well plates to 60% confluency, and then treated with
Tam or E2, alone or in combinations. Cells were fixed
with 4% paraformaldehyde and incubated overnight at
4°C with primary antibodies diluted (1:300) in PBS. After
three subsequent washes in PBS, cells were incubated at
room temperature for 1 h with FITC-conjugated second-
ary antibodies (goat anti-rabbit IgG). The specificity of
immunofluorescence was determined in the absence of
hSSTR-specific antibodies.
Cell Proliferation Assay
Cell proliferation was assessed 72 h post-treatment by the
MTT method. Cells were seeded at 1000 cells/well in 96-
well plates containing 100 µl of standard medium. Treat-
ments were started, as described above, 24 h later. At the
end of the treatment period, 25 µl MTT solution, 5 mg/ml
in PBS was added to each well. Following 2 h incubation
at 37°C, 100 µl stop solution (50% dimethyl-formamide,
50% H2O, 20% SDS, pH 4.7) was added to each well and
cells were incubated for an additional 20 h to solubilize
the crystallized dye. Optical densities of the solutions, in
each well, were determined by spectrophotometer.
Statistical Analysis
Results are expressed as means ± SE. Statistical significance
was determined using the Student's unpaired t test.
Results
Effects of Tamoxifen and Estradiol on SSTR1 and SSTR2 
mRNA and Protein Expression in ZR-75-1 Cells
In order to assess the effects of Tam and E2 on SSTR1 and
SSTR2 expression, we first determined dose-dependent
changes in mRNA expression. In the ER-positive breast
cancer cell line ZR-75-1, Tam treatment resulted in a sig-
nificant increase in SSTR1-mRNA, up to 2.2-fold in com-
parison to non-treated cells, at high concentrations (10
nM and 1 µM) (Fig. 1A). In contrast, E2 treatment signifi-
cantly decreased SSTR1-mRNA expression by >25%.
Treatment with both Tam and E2 resulted in a further
decrease in SSTR1 mRNA levels. In contrast, both Tam andJournal of Carcinogenesis 2005, 4:10 http://www.carcinogenesis.com/content/4/1/10
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E2 increased SSTR2 mRNA expression. However, the effect
of Tam was stronger (4.5 fold increase at 1 µM) in addi-
tion to being dose-dependent (Fig. 1B). In this case,
simultaneous treatment with Tam and E2 had no signifi-
cant effect on SSTR2 mRNA expression as compared with
control (Fig. 1B).
We further extended our study and determined the cellu-
lar distribution of SSTR1 and SSTR2 by indirect immun-
ofluorescence using SSTR1- and SSTR2-specific
antibodies. As shown in Fig. 2, in ZR-75-1 cells, the
changes observed after a 30–36 h treatment were compa-
rable to changes described at the mRNA level. In control
cells, SSTR1 and SSTR2 immunoreactivity had patchy dis-
tributions on the cell surface. Upon Tam treatment, SSTR1
and SSTR2 immunoreactivity significantly increased and
the receptors were more uniformly expressed on the cell
surface (Fig. 2B and 2F). Treatment with E2 alone or in
combination with Tam resulted in either decreased
expression or no significant changes in SSTR1- and SSTR2-
like immunoreactivity at all time-points (Fig. 2C,D,G and
2H).
Effects of Tamoxifen and Estradiol on SSTR1 and SSTR2 
mRNA and Protein Expression in T47D Cells
To assess whether these effects were similar in other ER-
positive cell lines, we studied T47D cells. Under estrogen-
free conditions, non-treated T47D cells express mRNA for
both SSTR1 and SSTR2 (Fig. 3A and 3B). SSTR1 mRNA
exhibited a biphasic response to Tam treatment, slightly
decreasing with 0.1 nM Tam while increasing by up to
~300% with 1 µM (Fig. 3A). In contrast, E2 down regu-
lated SSTR1 mRNA. Combined treatment caused a greater
decrease in SSTR1 mRNA levels compared to E2-treated
cells. In comparison, SSTR2-mRNA in T47D cells
increased with Tam or E2. However, the combined treat-
ment did not significantly change SSTR2 mRNA expres-
sion compared to control cells (Fig. 3B). In order to
examine the cellular distribution of SSTR1 and 2 in
response to Tam and E2, alone or in combination, on
receptor expression at the protein level, T47D cells were
also studied by indirect immunofluorescence. In control
cells (Fig. 4), both receptors are expressed as membrane
proteins. SSTR1 and 2, immunoreactivity decreased in
T47D cells upon 30–36 h treatment with either Tam or E2,
alone or in combination. Furthermore, a punctate pattern
of receptor immunoreactivity was detected in all treated
cells (Fig. 4).
Effects of Tamoxifen and Estradiol on SSTR1 and SSTR2 
Expression in MDA-MB-231 Breast Cancer Cells
We next examined the effects of Tam and E2 in ERα -nega-
tive breast cancer cells MDA-MB-231. At baseline condi-
tions, cells appeared to express a low amount of SSTR1-
Concentration dependent changes in SSTR1 (A) and 2 (B) mRNA in ZR-75-1 cells treated with Tam and E2 alone or in  combination Figure 1
Concentration dependent changes in SSTR1 (A) and 2 (B) mRNA in ZR-75-1 cells treated with Tam and E2 alone or in combi-
nation. Cells were treated with Tam and E2 for 24 h (see Materials and Methods for details). mRNA levels were determined by 
RT-PCR and expressed as OD ratio. Note a concentration-dependent increase in SSTR1 mRNA levels with Tam and 
decreased expression in the presence of E2 or combined treatment. SSTR2 mRNA levels increased in response to Tam or E2 
but not with combined treatment. Data presented are from three independent experiments performed in triplicate. A repre-
sentative ethidium bromide-stained gel image is shown. * p < 0.05Journal of Carcinogenesis 2005, 4:10 http://www.carcinogenesis.com/content/4/1/10
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Photomicrographs illustrating the immunohistochemical localization of SSTR1 and 2 in ZR-75-1 breast cancer cells Figure 2
Photomicrographs illustrating the immunohistochemical localization of SSTR1 and 2 in ZR-75-1 breast cancer cells. Cells were 
treated with 1 µM of Tam and E2, alone or in combination, for 30–36 h and labelled with anti-rabbit SSTR1 and 2 antibodies 
followed by FITC-conjugated goat anti-rabbit IgG. Note a significant increase in SSTR1 and 2-like immunoreactivity in response 
to Tam (B and F) and decreased staining in the presence of E2 (C and G). Upon combined treatment SSTR1 is less than control 
(D) but SSTR2 expression is comparable to the control (H). Scale bar = 25 µM.
Semiquantitative analysis of SSTR1 (A) and SSTR2 (B) mRNA in T47D cells treated with Tam and E2, alone or in combination,  for 24 h Figure 3
Semiquantitative analysis of SSTR1 (A) and SSTR2 (B) mRNA in T47D cells treated with Tam and E2, alone or in combination, 
for 24 h. mRNA levels were estimated by RT-PCR and expressed as OD ratio. SSTR1 gene expression increased in the pres-
ence of Tam but decreased with E2 and combined treatments in a concentration-dependent manner. SSTR2 gene expression 
increased in the presence of Tam as well as with E2 but not with the combined treatment. A representative ethidium bromide-
stained gel image is shown. Data presented are from three independent experiments performed in triplicate. * p < 0.05.Journal of Carcinogenesis 2005, 4:10 http://www.carcinogenesis.com/content/4/1/10
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Photomicrographs depicting the immunohistochemical localization of SSTR1 and 2 in T47D breast cancer cells Figure 4
Photomicrographs depicting the immunohistochemical localization of SSTR1 and 2 in T47D breast cancer cells. Cells were 
treated with 1 µM Tam and E2, alone or in combination, for 30–36 h and processed for localization of SSTR1 and SSTR2 as 
described in Fig. 2. Note the significant changes in distributional pattern of SSTR 1 (A–D) and 2 (E–H) like immunoreactivity 
upon treatment. In control cells, both receptors are uniformly expressed as membrane proteins; however, upon treatment, a 
punctated receptor-like immunoreactivity was noticed at the cell surface. Scale bar = 25 µM.
Concentration-dependent changes in SSTR1 and 2 mRNA in MD-MB231 cells treated with Tam or E2, alone or in combination,  for 24 h Figure 5
Concentration-dependent changes in SSTR1 and 2 mRNA in MD-MB231 cells treated with Tam or E2, alone or in combination, 
for 24 h. mRNA levels were determined by RT-PCR and expressed as OD ratio. No significant changes in receptor expression 
were seen except for SSTR1 in presence of 10 nM of Tam and SSTR2 at the lower concentration of E2. Data presented are 
from three independent experiments performed in triplicate. A representative ethidium bromide-stained gel image is shown. * 
p < 0.05.Journal of Carcinogenesis 2005, 4:10 http://www.carcinogenesis.com/content/4/1/10
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mRNA in comparison to SSTR2 (Fig. 5). Tam treatment
significantly increased SSTR1-mRNA at a 10 nM concen-
tration (Fig. 5A). The increase observed in SSTR2 with
Tam was modest and did not reach statistical significance
(Fig. 5B). Similar changes occurred when cells were
treated with E2: both SSTR1 and SSTR2-mRNA were
upregulated; however, in this case, the effect on SSTR2 was
stronger. The combined treatment resulted in a trend
towards down-regulation of SSTR1-mRNA while there
was no significant change in SSTR2-mRNA compared to
control.
Similarly, very mild SSTR1 and SSTR2 immunoreactivity
was observed in MDA-MB-231 cells under basal condi-
tions (Fig. 6). The distribution followed a diffuse punctate
pattern for both receptors. SSTR1 and SSTR2 were upregu-
lated after Tam treatment while SSTR2 immunoreactivity
was also upregulated by E2. Combined treatment was also
associated with modest increases in SSTR1 and SSTR2
immunoreactivity.
SSTR1 Selective Agonist Accelerates the Tamoxifen-
Induced Inhibition of ZR-75-1 Cell Proliferation
As illustrated in Fig. 7, the SSTR1-specific agonist potenti-
ated the antiproliferative effects of Tam in ZR-75-1 cells.
Cells were pretreated with Tam and E2, alone or in com-
bination, for 30 h and then exposed to SSTR1-selective
agonist for 42 h. Upon treatment with Tam alone, a signif-
icant reduction in cell proliferation was observed in ER-
positive breast cancer cells. Combining SSTR1-specific
agonist with Tam further suppressed proliferation when
compared with Tam alone. It is worth noting that treat-
ment with SSTR1 agonist alone had no significant effect
on cell proliferation. Interestingly, when both Tam and E2
were given simultaneously followed by SSTR1 agonist,
there was a mild but significant decrease in cell prolifera-
tion rate. Furthermore, in T47D and MDA-MB-231 cells,
pretreatment with Tam followed by SSTR1-specific ago-
nist resulted in mild, yet non-significant, additional inhi-
bition of proliferation compared with Tam alone (data
not shown).
Discussion
In the present study, we demonstrate the roles of Tam and
E2 on SSTR1 and SSTR2 mRNA and protein expression in
ER-positive and ER-negative cells. This is the first study
that not only systematically analyses the regulation of
SSTR by E2 and Tam in breast cancer cells at both the
mRNA and protein levels, but also demonstrates how this
translates into changes in cancer cell proliferation control
with somatostatin analogs. Our first observation was the
contrasting effects of E2 and Tam on SSTR1 in ER-positive
cells. An inhibitory effect of E2 on SSTR1-mRNA has been
previously reported in rat anterior pituitary cells [17].
SSTR1 has been shown to inhibit cell proliferation and
migration of tumor cells [30-33]. Therefore, it is most
likely that its down-regulation by E2 plays a role in the
proliferative effect of E2 in susceptible tissues. Likewise,
the observed up-regulation of SSTR1 by Tam may
represent an important mechanism whereby Tam exerts
Photomicrographs illustrating the immunohistochemical localization of SSTR1 (A–D) and SSTR2 (E–H) in the ERα  negative  MDA-MB-231 breast cancer cells Figure 6
Photomicrographs illustrating the immunohistochemical localization of SSTR1 (A–D) and SSTR2 (E–H) in the ERα  negative 
MDA-MB-231 breast cancer cells. Cells were treated with 1 µM Tam and E2, alone or in combination, for 30–36 h and proc-
essed for localization of SSTR1 and SSTR2 (see Fig. 2 for details). MDA-MB-231 cells exhibited weak expression of both recep-
tors. Note the apparent intracellular localization of the receptors like immunoreactivity. Scale bar = 25 µM.Journal of Carcinogenesis 2005, 4:10 http://www.carcinogenesis.com/content/4/1/10
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an inhibitory effect on tumor progression. In CCL39
human fibroblasts expressing SSTR1, SST inhibited activa-
tion of Rho (a key regulator of the actin-based cell
cytoskeleton), thereby inhibiting the assembly of focal
adhesions and actin stress fibres, and impairing cell
migration [30]. This effect was not seen in cells expressing
only SSTR2. Moreover, SSTR1-expressing cells from GH-
and PRL-secreting adenomas and medullary thyroid
cancer exhibited inhibition of hormone secretion in addi-
tion to reduced cell viability in response to SSTR1-specific
agonist [31,32].
SSTR2 mRNA up-regulation by both Tam and E2 is in
agreement with previous studies in T47D cells but differs
from what has been previously shown in ZR-75-1 and
MDA-MB-231 cells [14,15]. Xu et al [14] observed no
effect of E2 in MDA-MB-231 cells, while we found that
these cells responded to nanomolar concentrations of
Tam and E2 with upregulation of SSTR1 and SSTR2
mRNA. This discrepancy can be explained by the different
methods used: nuclease protection assay by Xu et al, and
RT-PCR by us, the latter being more sensitive to small
changes. Furthermore, Xu et al showed in ZR-75-1 cells
that only E2 caused SSTR2 upregulation while Tam
opposed this effect. It has been shown that exposure to E2
can increase ERβ  mRNA expression in breast cancer cells
[39]; conversely, prolonged E2 deprivation can induce
loss of ER expression in some breast cancer cell lines [40].
Therefore, we speculate that differences in the E2-free
pretreatment period (48 h in Xu et al vs. 24 h in our
experiments) could have altered ER expression at the time
of treatment. Additionally, the use of Tam in our experi-
ments vs. the active metabolite OH-tamoxifen (a product
SSTR1 selective agonist enhanced the antiproliferative effects of Tam in ZR-75-1 cells Figure 7
SSTR1 selective agonist enhanced the antiproliferative effects of Tam in ZR-75-1 cells. Cells were pre-treated with Tam or E2 
for 30 h. after the initial 30 h. Subsequently, a non-peptide SSTR1-specific agonist (R1 agonist) was added, as indicated, and cells 
were cultured for an additional 42 h. Cell proliferation was determined by MTT assay as described in Material and Methods. 
Data are presented as proliferation index in comparison to control as an arbitrary unit.Journal of Carcinogenesis 2005, 4:10 http://www.carcinogenesis.com/content/4/1/10
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of liver metabolism of Tam in vivo) in the experiment of
Xu et al may be responsible for these differences.
Given the fact that in ERα -negative cells, E2 and Tam dis-
played similar effects, our data provide evidence that the
upregulation of SSTR2-mRNA by ER agonists is, at least in
part, independent of ERα . Contrary to previous beliefs,
the classical ER-negative breast cancer cell line MDA-MB-
231 expresses low levels of ERβ  but no ERα  [39]. Kimura
et al [41] have recently shown estrogen sensitive
sequences in the promoter region of SSTR2 gene. Further
studies are required to delineate the exact molecular
mechanisms involved. Given that the affinity of Tam for
the ER is lower than that of its metabolite OH-tamoxifen
or E2 [42], it is not surprising that simultaneous treatment
with equimolar concentrations of E2 and Tam resulted in
down-regulation of SSTR1 as seen when E2 was given
alone. It is remarkable; however, that the effect was
stronger with the combined treatment and that, in the
case of SSTR2, the combined E2 and Tam treatment
resulted in loss of the upregulatory effect of either com-
pound alone. These effects probably involve interactions
between ERs and their coregulators, and may include E2
upregulation of ERβ  expression and induction of the for-
mation of ERα /ERβ  heterodimers with decreased tran-
scriptional activity [43,44].
Of interest, we detected surprising changes in the pattern
of subcellular distribution of the receptors as a result of
the treatments used. Basically, Tam changed the pattern of
expression of SSTR1 and SSTR2 in ZR-75-1 cells from
patchy to a more homogeneous cell surface distribution.
In contrast, both Tam and E2 altered the homogeneous
distribution of receptors in T47D cells to a more irregular
patchy distribution. These changes in SSTR1 and SSTR2
immunoreactivity may involve receptor homo- or het-
erodimerization, receptor complex dissociation and/or
internalization [45,46]. These could be a specific effect of
ER activation or the result of changes in the fluidity and/
or composition of the cell membrane. The ability of Tam
to affect membrane stability by decreasing its fluidity has
been previously shown. There are reports of Tam decreas-
ing synthesis of glycosphingolipids by blocking synthesis
of their precursor, glycosylceramide, thereby causing
intracellular ceramide accumulation and membrane dis-
ruption [47].
In summary, our data show that SSTR1 and SSTR2 expres-
sion in breast cancer cells is modulated by Tam and E2 in
a cell-specific manner. SSTR1 expression is upregulated by
Tam while E2 and combined treatment preferentially
downregulate this receptor in ER-positive cells. In ERα -
negative cells, both ligands caused upregulation of SSTR1.
The changes in subcellular distribution of SSTR1 and
SSTR2 were favourable in only one of the ER-positive cell
lines investigated (ZR-75-1). These cells also showed a
stronger growth inhibitory response to SSTR1-agonist fol-
lowing pretreatment with Tam. Therefore, SSTR1 activa-
tion appears to be a potentially important mechanism for
tumor cell growth control. For this reason, enhancing
SSTR expression in tumor cells could make them more
susceptible to growth inhibition by SSTR agonists, partic-
ularly SSTR1 agonists, as anti-neoplastic treatment. Our
study suggests that SERMs like Tam may have such effects.
These results have important implications in our under-
standing of the role of SSTRs in ER responsiveness of
breast cancer. Moreover, it might not be premature to
anticipate that, based on our results, some breast cancer
patients may benefit from SSTR1-selective agonist therapy
in combination with Tam, in an estrogen-depleted milieu.
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